Introduction
This study was designed to identify the set of functions activated in cultured endothelial cells by the hematopoietic growth factors, granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage-colony-stimulating factor (GM-CSF), and to compare them with those elicited by prototypic cytokines active on these cells. Moreover, indications as to the in vivo relevance of in vitro effects were obtained. G-CSF and GM-CSF induced endothelial cells to proliferate and migrate. In contrast, unlike appropriate reference cytokines (IL-1 and tumor necrosis factor, IFN-'y), G-CSF and GM-CSF did not modulate endothelial cell functions related to hemostasisthrombosis (production of procoagulant activity and of platelet activating factor), inflammation (expression of leukocyte adhesion molecule-i and production of platelet activating factor), and accessory function (expression of class II antigens of MHC). Other colony-stimulating factors (IL-3 and macrophage-colony-stimulating factor) were inactive on all functions tested. In comparison to basic fibroblast growth factor (bFGF), G-CSF and GM-CSF induced lower maximal proliferation of endothelial cells, whereas migration was of the same order of magnitude. G-CSF and GM-CSF stimulated repair of mechanically wounded endothelial monolayers. Exposure to both cytokines induced shape changes and cytoskeletal reorganization consistent with a migratory phenotype. To explore the in vivo relevance of the in vitro effects of these cytokines on endothelium, we studied the angiogenic activity of human G-CSF in the rabbit cornea. G-CSF, but not the heat-inactivated molecule, had definite angiogenic activity, without any sign of inflammatory reactions. G-CSF was less active than bFGF. However, the combination of a nonangiogenic dose of bFGF with G-CSF resulted in an angiogenic response higher than that elicited by either individual cytokines. Thus, G-CSF and GM-CSF induce endothelial cells to express an activation/differentiation program (including proliferation and migration) related to angiogenesis. (J. Clin. Invest. 1991. 87:986-995.) Key words: angiogenesis * chemotaxis * cellular growth -cytokines * colonystimulating factors A family ofglycoprotein molecules, termed colony-stimulating factors (CSF),' control proliferation, maturation, and functional activities of granulocytes, macrophages, and their precursors (1) (2) (3) . Granulocyte (G)-and granulocyte-macrophage (GM)-CSF regulate cells belonging to the myelomonocytic differentiation pathway. Until recently, G-and GM-CSF were considered growth and differentiation factors with a spectrum of action restricted to the hematopoietic system (1) (2) (3) . Recent evidence indicates that nonhematopoietic elements, including solid tumor lines (4-6), bone marrow fibroblasts (4) , and keratinocytes (7) respond to G-and GM-CSF. We have shown that human endothelial cells derived from umbilical vein (HU-VEC) and a human endothelial hybrid cell line (EAhy926) have high affinity receptors for G-and GM-CSF (8) , similar in number and affinity to those present on myelo-monocytic cells (1) (2) (3) . Unlike myelo-monocytes and endothelial cells, other cell types studied in this respect have low affinity GM-CSF receptors (5, 9) .
After binding to their receptors on HUVEC, G-and GM-CSF start sequential early events, including a rise ofintracellular pH (10) and expression of the c-fos protooncogene (8) , followed by cell migration and proliferation (8, 10) . G-CSFtreated bovine endothelial cells also release plasminogen activator (1 1), an event commonly associated with migration (12) . Thus, G-and GM-CSF are among the cytokines that modulate the functional status of endothelial cells (13) (14) (15) .
Cytokine-elicited endothelial cell responses follow distinct, largely nonoverlapping, differentiation/activation programs (15) . IL-1 and tumor necrosis factor (TNF) induce proinflammatory/prothrombotic changes in endothelial cells. These include production ofprocoagulant activity (PCA) (16-19), prostaglandins (20, 21) , platelet-activating factor (PAF) (22, 23) , and plasminogen activator inhibitor (24) , inhibition of plasminogen activator synthesis (24) , alterations in the thrombomodulin/protein C anticoagulation pathway (19, 25), expression of endothelial-leukocyte adhesion molecule-1 (ELAM-1) (26, 27), and upregulation of intercellular adhesion molecule-1 (28, 29) . IFN-y induces class II antigens ofMHC in endothelial cells (30, 31) , a crucial determinant of accessory cell function.
Finally, fibroblast growth factors (FGF) (32, 33), transforming growth factors (34, 35) , and epidermal growth factor (36) control functions (proliferation and migration) related to angiogenesis.
The aim of this study was to characterize the set ofendothelial cell functions modulated by G-and GM-CSF and to compare these cytokines with prototypic polypeptide mediators active on endothelium (IL-1 and TNF, IFN-y, basic-FGF). Furthermore, we searched for indications as to whether the in vitro effects of G-and GM-CSF (i.e., induction of migration and proliferation) have in vivo relevance.
Methods
Cytokines. Human (8) .
Cell cultures. HUVEC were grown in M199 supplemented with 20% FCS (Gibco Laboratories, Grand Island, NY), endothelial cell growth factor (100 ,ug/ml, Sigma Chemical Co., St. Louis, MO) and porcine heparin (100 ig/ml, Sigma) and used at early passages (I-IV). No leukocyte contamination was observed by FACS analysis of cells stained with monoclonal antibodies anti-CD 1 lb, Mo2, and T3 (8, 10, 22 (10 p1/droplet) and allowed to evaporate. The repolymerized pellets were further evaporated at 4°C overnight. The angiogenic assay was performed using corneas of adult outbred New Zealand rabbits weighing 2-3 kg (43). In the lower corneal half of anesthetized animals (pentobarbital, 25-30 mg/kg) pockets were produced into half of the thickness ofthe comeal stroma using a pliable iris spatula 1.5 mm in width. The bottom ofeach pocket was kept at 2 mm from the limbal vessel. Elvax-40 pellets were placed into the preformed corneal pockets. In some experiments, the standard protocol was modified by producing two adjacent pockets, 2 X 3 mm each, as previously reported (44) . Subsequent daily observations of the implants were made with a slit lamp stereomicroscope without anesthesia. An angiogenic response was considered valid when budding of vessels from the limbal plexus occurred at 3-4 d and persisted for at least 2 wk from the surgical implant. Angiogenesis was expressed as the number of implants exhibiting neovascularization of normally avascular corneal stroma over the total implants performed. Neovascularization was also recorded and scored by the number of newly formed vessels and by their growth rate. An arbitrary five point ordinal scale ranging from 0 to 4 was used to quantify the potency of the angiogenic response on the basis of the number of newly formed vessels produced by the tested compounds: 0, no vessel growth; 1+, equivocal vessel growth from the limbus to 0.6 mm over the limbus; 2+, evident new vessel formation extending midway to the corneal pocket; 3+, prominent new vessel formation reaching the corneal pocket; 4+, extensive neovascularization extending into the comeal pocket and surrounding the implant. The occurrence of an inflammatory reaction accompanying neovascularization was also investigated at macroscopic level by scoring the presence of corneal opacity and at microscopic level by histological examination of the corneal explants obtained after 3-12 d of observation. Corneal explants were fixed by immersion in 10% phosphate-buffered formalin. Serial paraffin (7-Mm sections) were stained with hematoxylin and eosin.
Results
Effects ofG-and GM-CSF on HUVEC in relation to prototypic cytokines. A major objective of this study was to define the set of responses elicited by G-and GM-CSF in HUVEC and to compare it with prototypic cytokines active on these cells. We examined functions related to thrombosis and inflammation (PCA, PAF, expression of leukocyte adhesion structures, such as ELAM-1), to accessory activity (HLA-Dr antigens), to angiogenesis (proliferation and migration). IL-1 a/TNFa, IFN-'y, and bFGF served as reference cytokines which activate HU-VEC for distinct sets of functions. As shown in Table I , G-and GM-CSF induced migration and proliferation of HUVEC, but failed to affect all other parameters examined. Table I summarizes the results obtained at one concentration (100 ng/ml) of G-and GM-CSF, respectively, and for one exposure time, optimal for the parameters and reference cytokines examined (see legend to Table I and Methods). For instance, PCA was measured at 4 h, when maximal stimulation of HUVEC by IL-1 a (10 ng/ml) and TNFa (10 ng/ml) is observed (Table I and 16,  18 ). It must be emphasized that a range ofconcentrations ofGand GM-CSF (from 0.1 to 500 ng/ml) and exposure times (from 2 to 72 h) were studied (not shown) with results consistent with those selected for display in Table I . Thus, G-and GM-CSF induced migration and proliferation of HUVEC without affecting functions related to inflammation, thrombosis, and accessory activity. When compared with the cytokine selected as reference agent for migration and proliferation (bFGF), the maximal proliferative response elicited by CSFs was substantially less (Table I and Fig. I A) . In a series ofexperiments (n = 10), G-, GM-CSF, and bFGF caused 1.5-fold (range 1.2-5), 1.5-fold (range 1.15-3.1), and 2.2-fold (range 2-8) increment of proliferation, respectively. CSFs-induced HUVEC migration was ofthe same order of magnitude as that induced by bFGF (Table I and Fig. 1 B) .
We also examined the effect of combined exposure of HU-VEC to CSFs and bFGF. Fig. 2 presents two experiments out of ten performed with G-CSF. Similar results were obtained with GM-CSF (not shown). No evidence of synergism was obtained in terms ofproliferation and migration using both optimal and suboptimal concentrations of the two cytokines. At most, an additive effect was observed, particularly in the migration assay (Fig. 2 B) , or in the proliferation assay with suboptimal concentrations of G-CSF (Fig. 2 A) . The combination of optimal concentrations of G-CSF with bFGF resulted in an inhibitory effect on proliferation (Fig. 2 A) . The experiment summarized in Fig. 2 was performed with simultaneous exposure to the two cytokines. No reciprocal potentiation was also observed when HUVEC were exposed to G-or GM-CSF for 24 h and then examined for responsiveness to bFGF in terms of migration and proliferation, and vice versa (not shown). It was of interest to evaluate whether other hematopoietic growth factors shared the ability of G-and GM-CSF to affect HUVEC. As shown in Table II , IL-3 and M-CSF did not affect either the migration and proliferation or the production of PCA and PAF by HUVEC.
Induction of HUVEC monolayer wound repair by G-and GM-CSF. The above results indicate that G-and GM-CSF induce proliferation and migration across pores ofpolycarbonate filters ofsparsely seeded HUVEC. It was ofinterest to evaluate the effect of G-and GM-CSF under conditions that more closely resemble those ofthe monolayer lining of blood vessels. These experiments were also prompted by a recent report indicating that TNF has different effects on sparse versus confluent endothelial cells (45) . We therefore examined the effect of Gand GM-CSF on the repair of a mechanically induced wound of HUVEC monolayers. Fig. 3 illustrates the G-CSF-induced repair of wounded monolayers and Table III presents a quantitative assessment ofthis activity. The effect of G-CSF in inducing wound repair is time (Fig. 3, a-d ) and dose dependent (Fig.  3, e-h ). After 6 h of stimulation with 100 ng/ml G-CSF, some cells move into denuded areas (Fig. 3 b) , and they almost completely occupy the free space within 24 h. The maximal activity is observed at 100 ng/ml of G-CSF (Fig. 3 h) , whereas it was almost negligible with 0.1 ng/ml (Fig. 3 e) . When HUVEC were treated for 60 min at 37°C with mitomycin C (1 ,ug/ml), 5 5 Student-Neuman-Keuls 140F (nCg/m) -5 5 test: control vs. G-CSF, 10 ng/ml; G-CSF, 100 ng/ml; bFGF, 1 ng/ml; bFGF, 5 ng/ml; G-CSF, 10 ng/ml + FGF 1 ng/ml; G-CSF, 10 ng/ml + bFGF 5 ng/ml; G-CSF, 100 ng/ml + bFGF 1 ng/ml; G-CSF, 100 ng/ml + bFGF 5 ng/ml; bFGF, 1 ng/ml vs. bFGF 5 ng/ml; G-CSF 10 ng + bFGF, 1 ng/ml; G-CSF, 10 ng/ml + FGF 1 ng/ml; G-CSF, 100 ng/ml + bFGF 5 ng/ml; bFGF, 5 ng/ml vs. G-CSF 10 ng/ml; G-CSF, 100 ng/ml; G-CSF, 100 ng/ml + bFGF, 1 ng/ml; G-CSF, 10 ng/ml + bFGF, 1 ng/ml vs. G-CSF, 10 ng/ml; G-CSF, 100 ng/ml; G-CSF, 10 ng/ml + bFGF, 5 ng/ml; G-CSF, 100 ng/ml + bFGF, 1 ng/ml; G-CSF, 10 ng/ml + bFGF, 5 ng vs. G-CSF, 100 ng/ml + bFGF, 1 ng/ml; G-CSF, 100 ng/ml + bFGF, S ng/ml. In migration experiments, the following comparisons gave P < 0.05 by Student-Neuman-Keuls test: G-CSF, 0.05 ng/ml vs. G-CSF, 5 ng/ml; bFGF, 0.1 ng/ml; bFGF, 1 ng/ml; G-CSF, 0.05 ng/ml + bFGF, 0.1 ng/ml; G-CSF, 0.05 ng/ml + bFGF, 1 ng/ml; G-CSF, 5 ng/ml + bFGF, 0.1 ng/ml; G-CSF, 5 ng/ml + bFGF, 1 ng/ml; G-CSF, 5 ng/ml vs. bFGF, 0.1 ng/ml; G-CSF, 0.05 ml/ng + bFGF, 0.1 ng/ml; G-CSF, 5 ng/ml + bFGF, 1 ng/ml; bFGF, 0.1 ng/ml; bFGF, 1 ng/ml; G-CSF, 5 ng + bFGF, 0.1 ng/ml; G-CSF, 5 ng/ml + bFGF, 0.1 ng/ml; G-CSF, S ng/ml + bFGF, 1 ng/ml; bFGF, 1 ng/ml vs. G-CSF, 0.05 ng/ml + bFGF, 0.1 ng/ml; G-CSF, 0.05 ng/ml + bFGF, 1 ng/ml; G-CSG, 5 ng/ml + bFGF, 0.1 ng/ml; G-CSF, 5 ng/ml + bFGF, 1 ng/ml; G-CSF, 0.05 ng/ml + bFGF, 0.1 ng/ml vs. G-CSF, 0.05 ng/ml + bFGF, 1 ng/ml; G-CSF, 5 ng/ml + bFGF, 0.1 ng; G-CSF, 5 ng/ml + bFGF, 1 ng/ml; G-CSF, 0.05 ng/ml + bFGF, 1 ng/ml vs. G-CSF, 5 ng/ml + bFGF, 1 ng/ml.
washed, and then stimulated with 100 ng/ml of G-CSF, the wound repair observed after 24 h was partially blocked (not shown). This suggests that G-CSF-induced repair required both migration and DNA synthesis. Boiled and biologically inactive G-CSF (100 ng/ml) (8) and IL-3 (up to 100 ng/ml) did not induce wound repair, whereas GM-CSF (from 1 ng/ml to 100 ng/ml) did so (not shown). Under the same conditions, bFGF (5 ng/ml) was also able to induce complete wound repair by 18-24 h (data not shown).
Cell migration was also quantified by counting the number of HUVEC that had moved after 6 h into the denuded area.
The migration was quantified by observing cells with a grid marked in increments of 100 ,um (Table III) . G-and GM-CSF showed a dose-dependent effect and had an equivalent potency in inducing HUVEC migration. The number of cells migrated in the first, second, and third 100-t.m segment in the presence I of an optimal concentration ofG-or GM-CSF is 100-, 80-, and 50-fold higher than in unstimulated monolayers. Boiling Gand GM-CSF abolished the activity as well as antibodies against G-CSF and GM-CSF. Basic FGF had similar effects, but at lower concentrations than that of active G-and GM-CSF. IL-3 and M-CSF were ineffective (Table III) .
Modification of HUVEC cytoskeleton induced by G-and GM-CSF. Migrating cells undergo shape changes with characteristic cytoskeletal reorganization. Hence, it was of interest to study the cytoskeletal structures of HUVEC exposed to G-and GM-CSF. Upon staining with R-PHD that specifically binds to F-actin, resting HUVEC showed an elaborate array ofmicrofilament bundles of the stress fiber type (Fig. 4 a) and scattered vinculin streaks, which correspond to areas of focal contact of the ventral membrane with the adhesion substratum (Fig. 4 b) . 1 h upon G-CSF (100 ng/ml) or GM-CSF (100 ng/ml) (not shown), stress fibers partially disappeared (Fig. 4 c) , vinculin streaks moved at the cells periphery and to the "tail" (Fig. 4 d) and cells assumed a typical migratory phenotype. Angiogenic activity ofG-CSF. In an effort to explore the in vivo relevance of the induction of endothelial cell migration and proliferation by G-and GM-CSF, we studied angiogenesis in the rabbit cornea. For these experiments we used G-CSF since this molecule, unlike GM-CSF, is not species-restricted: human G-CSF is in fact active in vitro and in vivo in rodents (46) (47) (48) . the number of cells migrating into the wound gap in 24 h was almost negligible with 0.1 ng/ml (e) and increased with 1 ng/ml (f), 10 ng/ml (g), and 100 ng/ml, to reach nearly complete repair (h). Bar denotes 28 Aim. 
45±12 27±8 12±4 G-CSF (100 ng/ml) 113±27 86±11 51±17 Boiled G-CSF (100 ng/ml) 10±3 0 0 G-CSF (100 ng/ml) +anti-G-CSF 8±2 0 0 G-CSF+ irrelevant IgG 145±20 81 ± 18 54±12 GM-CSF (1 ng/ml) 11±4 0 0 GM-CSF (10 ng/ml) 65±21 34±17 14±3 GM-CSF (100 ng/ml) 126±18 90±19 61±20 Boiled GM-CSF (100 ng/ml) 9±2 0 0 GM-CSF (100 ng/ml) +anti-GM-CSF (1:500 dilution) (a 1:1,000 dilution neutralized 500 U), respectively.
In a first set ofexperiments we assayed the angiogenic activity ofG-CSF, and its potency was compared to bFGF, a known angiogenic effector (12, 33) . As shown in Table IV , G-CSF at a dose of 50 ng/pellet was able to promote new vessel growth in 50% of the implants (6 positive implants out of 12, P < 0.05 versus implants containing Elvax alone by Fisher exact test). Increasing the dose tested (100 ng/pellet) did not modify the angiogenic response. G-CSF at a concentration of 10 ng/pellet was almost devoid of any angiogenic activity (1 positive out of 9) (Table IV) . The newly formed vessel network consisted of (Fig. 5 a and Fig. 6 ). Histological sections of corneal specimens obtained 12 d after the implant showed the presence of several well-defined capillaries (Fig. 6  b) . No macroscopic or microscopic signs of an accompanying inflammatory reaction were observed as stated by persistence of corneal transparency (Fig. 5) and by the absence of any inflammatory infiltrate in the histological sections (Fig. 6 ). When G-CSF was heat inactivated, its angiogenic activity was consistently reduced (Table IV) . Implanted bFGF produced a consistent angiogenic response (80-100 capillaries enveloping the implant by day 12) at a dose of 50 ng/pellet (Table  IV) . At lower doses, only few implants hinted an angiogenic response which, at best, produced 5-10 capillaries budding from the limbus and never progressing over half the way to reach the implanted pellet (Table IV and Fig. 5 b) . Figure 5 . Effect of G-CSF on angiogenesis. G-CSF (50 ng/pellet) induced the formation of slowly progressing newly formed capillaries into the cornea stroma (a). When G-CSF was assayed with a nonangiogenic dose of bFGF (10 ng/pellet) (b), cornea neovascularization appeared more consistent and efficient in terms of vessel number and growth velocity (c). Heat inactivation of G-CSF produced loss of angiogenic activity. The pictures represent implant of Elvax-40 pellets into two separate pockets. In panels A and B, G-CSF and bFGF were assayed in the presence of a control pellet. All photographs (x 18) were taken at day 12 from the surgical implants through a slit lamp stereomicroscope (Olympus Corp. of America, New Hyde Park, NY). Arrows indicate a white spot produced by light reflex. G, G-CSF; F, bFGF; hG, heat-inactivated G-CSF; E, Elvax pellet.
In a second set of experiments we wanted to examine whether G-CSF acted in concert with bFGF in inducing neovascularization. Implanted bFGF was used at doses unable per se to elicit a fully competent vascular network (Table IV and Fig.  5 b) . The two cytokines were placed in separate adjacent pockets to avoid any physical interactions. As shown in Table IV and in Fig. 5 c, 
Discussion
The results presented here identify the set of functions induced in HUVEC by G-and GM-CSF in relation to prototypic cytokines active on this cell type. They confirm and extend our original observations that G-and GM-CSF induced migration and proliferation of endothelial cells (8, 10) . Unlike appropriate reference cytokines (IL-1 a/TNFa, IFN-'y), G-and GM-CSF did not modulate endothelial cell functions related to hemostasis-thrombosis (synthesis of PCA and PAF), inflammation (expression of ELAM-l and synthesis of PAF), and accessory function (HLA-Dr). In comparison to bFGF, G-and GM-CSF induced lower maximal proliferation of HUVEC, whereas migration was of the same order of magnitude.
The proliferation and migration assays used routinely in this and previous studies (8, 10) , involved the use of sparsely seeded HUVEC. Gerlach et al. (45) recently reported substantial differences in the response (thrombomodulin activity, PCA, and barrier function) of sparse versus monolayer HU-VEC to TNF. We therefore examined the capacity of G-and GM-CSF to stimulate repair of mechanically wounded HU-VEC monolayers, a situation possibly more similar to in vivo conditions. The two CSF molecules stimulated wound repair by HUVEC. This phenomenon was partially inhibited by mitomycin C, an inhibitor of cell proliferation indicating that the wound repair induced by G-and GM-CSF is due to both migration and growth of HUVEC. This result is in agreement with our previous data showing that maximal motility in the Boyden chamber assay was observed after 6 h (8), and maximal uptake ofthymidine after 12 h (8) . Furthermore, previous studies (49) have shown that endothelium, at the leading edge of a wound, began DNA synthesis at -8-10 h and reached maximum at 20 h. The monolayer wound system also allowed an analysis of changes in the cytoskeleton of HUVEC exposed to G-and GM-CSF. HUVEC treated with G-or GM-CSF displayed a motile phenotype, characterized by leading edges and often a prominent tail, loss of their normal network of stress fibers and of vinculin streaks.
Having established that G-and GM-CSF induced endothelial cell migration and proliferation under different in vitro conditions, it was important to investigate the in vivo relevance ofthese observations. G-CSF was used for these studies because it is known to be non-species-restricted and to act in rodents (46) (47) (48) . G-CSF had relatively weak, but definite, angiogenic activity in the rabbit cornea. In view of the in vitro effects of G-CSF on HUVEC, it is reasonable to assume that the angiogenic effect of G-CSF in vivo reflects a direct interaction with endothelial cells. Thus, G-CSF (and, by inference, GM-CSF) belongs to the group of factors that induce angiogenesis via direct modulation of endothelial cell locomotion and growth, the prototypes of which are FGFs (32, 33) .
Having established that G-CSF has angiogenic activity in vivo, we wanted to obtain initial indications as to the capacity of this cytokine to act in concert with bFGF. By combining nonangiogenic doses of bFGF with G-CSF, we observed responses whose intensity is suggestive of a cooperative interaction ofthe two cytokine in inducing angiogenesis. The cooperative angiogenic activity of G-CSF and bFGF was evident in terms of response intensity (number of capillaries, number of positive implants, time to reach the pellets). This initial observation needs to be extended. However, the cooperative effect of G-CSF and bFGF in inducing in vivo angiogenesis is somewhat surprising and intriguing. In fact, in vitro, in spite of efforts involving different experimental designs only one of which is shown here (see Results), we have found no indication of a synergistic action of these two cytokines on HUVEC proliferation and migration. At best, an additive effect was observed. In vivo angiogenesis occurs as the end point of complex interactions between many events involving the remodeling of the extracellular matrix and the release of several "factors" (12, 50) . This apparent paradox of a combination of cytokines acting directly on endothelial cells, showing a cooperative effect in vivo, but not in vitro, adds to the list offactors or conditions for which in vitro modulation ofproliferation and migration is not necessarily predictive of in vivo effects on angiogenesis (12) .
Possible explanations for this partial discrepancy in the capacity of G-CSF to act in concert with bFGF in vitro and in vivo could involve a different biology ofmicrovascular endothelium versus HUVEC or effects of G-CSF on passing neutrophils.
Various cell types, including activated immunocompetent cells, fibroblasts, and endothelial cells themselves, can produce G-and GM-CSF (1-3). Thus, locally produced G-and GM-CSF could be part of the regulatory network of neovascularization and, in bone marrow, contribute to the maintenance ofthe hematopoietic microenvironment, of which endothelial cells are one important component.
